Limited time offer! 10% off your first blood test order!
PSA screening is recommended from age 50 — or age 40 for men with a family history. A simple fingerstick gives you the data to act.
or 4 interest-free payments of £9.75 with Klarna
Measure your PSA (prostate-specific antigen) level with a simple home fingerstick test. Recommended for men over 50, or over 40 with a family history.
Prostate-specific antigen (PSA) is a protein produced by the prostate gland. Elevated PSA levels can indicate prostate enlargement (benign prostatic hyperplasia), prostate inflammation (prostatitis), or prostate cancer. While PSA is not a definitive cancer test — and elevated levels have multiple potential causes — it is the most widely used screening marker for identifying men who warrant further investigation. The NHS Prostate Cancer Risk Management Programme offers PSA testing to men aged 50 and over who request it after discussion of the benefits and limitations. This test provides that same measurement with the added value of GMC-registered physician review and clear commentary on next steps relative to your result. Men with a family history of prostate cancer or of Black African or Caribbean heritage are advised to consider testing from age 40. All analysis is performed at a UKAS ISO 15189-accredited laboratory.
Understand what each marker measures, why it matters, and what the science says — not just a list of numbers.
This panel is designed for adults who want a comprehensive, evidence-based picture of their metabolic health — not a GP referral panel.
Men aged 50 and over who have not had a recent PSA check
Men of any age with a first-degree relative (father, brother) diagnosed with prostate cancer
Men of Black African or Caribbean heritage, who have two to three times the population average risk
Men with urinary symptoms (frequent urination, reduced flow, nocturia) wanting to check their prostate health
Men being monitored following previous elevated PSA or prostatitis
PSA is an organ-specific marker, not a cancer-specific marker. It is elevated in benign prostatic hyperplasia (BPH), prostatitis, and vigorous physical activity (particularly cycling or horse-riding), as well as prostate cancer. An elevated PSA requires further investigation — typically GP referral for digital rectal examination and consideration of MRI or biopsy — but does not constitute a cancer diagnosis. Conversely, a normal PSA does not exclude prostate cancer; approximately 15 percent of prostate cancers occur in men with PSA below 4 ng/mL. PSA velocity (the rate of change over time) is often more informative than a single result, which is why serial testing at annual intervals is recommended for men in higher-risk groups. This test is not a substitute for GP review or specialist urological assessment.
From order to physician-reviewed report in as little as three working days.
Home fingerstick kit delivered within 2 working days.
No ejaculation for 48 hours; no vigorous cycling or exercise for 48 hours before collection.
Pre-paid Royal Mail envelope included.
Secure online report with physician commentary in 3 to 5 working days.
Three options designed to fit your schedule, location, and preference — all producing a laboratory-standard sample.
Adults 18+ in mainland UK. Not suitable if you have had a transfusion in the last 3 months.
Order anytime; kit dispatched within 24 hours Mon–Fri.
Allow 24–48 hours for sample transit on top of lab processing time.
Adults 18+ within 20 miles of a serviced city centre.
Mon–Sun, 06:00–20:00. Next-day booking typical.
Sample reaches the lab within 24 hours of collection.
Adults 16+ with photo ID. Paediatric draws by appointment at selected sites.
Mon–Fri, with Saturday hours at most metropolitan locations.
Samples processed same-day at the receiving clinic.
Every test is processed in a UKAS ISO 15189-accredited laboratory, overseen by GMC-registered physicians, and governed by UK GDPR. No overseas processing, no offshore data.
Follow these guidelines to ensure accurate, reproducible results. Most markers are sensitive to recent food, exercise, and sleep.
Can't find your answer? Our clinical support team is available Monday to Friday, 9am–5pm.
Contact supportPSA reference ranges are age-adjusted. As a general guide, PSA below 2.5 ng/mL is considered normal for men under 60, below 3.5 ng/mL for men aged 60 to 69, and below 4.5 ng/mL for men aged 70 and over. However, these thresholds are guides rather than absolute cutoffs; the clinical significance depends on your age, ethnicity, symptoms, and the PSA trajectory over time. Men with PSA consistently above the age-adjusted range should be referred for further evaluation. Men with PSA in the range of 4 to 10 ng/mL have approximately a 25 percent chance of prostate cancer on biopsy; above 10 ng/mL the probability rises above 50 percent.
No. PSA elevation is common and has many causes other than cancer. Benign prostatic hyperplasia (BPH) — age-related prostate enlargement — is the most common cause of elevated PSA in men over 50. Prostatitis (prostate inflammation), vigorous prostate-stimulating activities such as cycling, and recent ejaculation all transiently raise PSA. An elevated result triggers further investigation — typically GP referral, digital rectal examination, and consideration of multiparametric MRI — which helps distinguish cancer from benign causes with far greater precision than PSA alone. Your physician commentary will clearly explain what level of concern your specific result warrants.
Current NHS guidance does not recommend universal annual PSA screening for all men, citing concerns about overdiagnosis of low-risk cancers that would never cause harm. However, individual risk assessment is different from population screening. Men who are at higher risk due to age (over 50), ethnicity (Black African or Caribbean heritage), or family history are increasingly advised by specialists to consider annual PSA monitoring so that a rising trajectory can be detected early. Your physician commentary will advise on the appropriate frequency of testing based on your result, age, and risk profile.
An elevated PSA result triggers a pathway of further investigation. Your physician commentary will recommend discussing the result with your GP, who can arrange a digital rectal examination and, if appropriate, referral to a urologist. NICE guidance now recommends multiparametric MRI (mpMRI) as the first-line investigation for elevated PSA, as this reduces unnecessary biopsies while maintaining sensitivity for clinically significant cancer. The MRI result, combined with your PSA level and any palpable prostate abnormality, guides the decision about whether a biopsy is needed.
Yes, and this is one of the most valuable uses of serial PSA testing. PSA velocity — the rate at which PSA increases over time — is often more clinically significant than any single reading. A PSA rise of more than 0.75 ng/mL per year is considered significant and warrants urological review even if the absolute level remains within the reference range. Annual testing from a recorded baseline allows you and your GP to detect concerning trajectories early, when intervention is most effective.
Yes. 5-alpha reductase inhibitors (finasteride, dutasteride), commonly prescribed for BPH or male pattern hair loss, reduce PSA by approximately 50 percent. Men on these medications need their PSA result doubled to obtain a comparable reading to an untreated baseline. Statins have also been shown in some studies to mildly lower PSA. If you are taking any of these medications, your physician commentary will flag the adjustment required for accurate interpretation.
